Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | TCF7 | P36402 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30855622 | 0.87 | EGFR (0.38) | EGFRTRPA1CTNNB1TCF7CDC7 | |
| SCHEMBL16364359 | 0.85 | TRPA1 (0.51) | TRPA1ARAPP | |
| SCHEMBL29427078 | 0.84 | KMO (0.55) | EGFRCTNNB1TCF7KMOPDE1C | |
| SCHEMBL422886 | 0.84 | KMO (0.55) | EGFRCTNNB1TCF7KMOPDE1C | |
| SCHEMBL424964 | 0.78 | TRPA1 (0.46) | TRPA1CTNNB1TCF7CDC7TRPM5 | |
| SCHEMBL29769166 | 0.78 | TRPA1 (0.46) | TRPA1CTNNB1TCF7CDC7TRPM5 | |
| SCHEMBL13137284 | 0.78 | HDAC8 (0.40) | EGFRMCL1KMOHDAC8ALDH1A1 | |
| SCHEMBL13548 | 0.77 | KMO (0.49) | EGFRMCL1KMOHDAC8NPC1 | |
| SCHEMBL13106517 | 0.77 | TRPM5 (0.57) | CTNNB1TCF7CDC7TRPM5NPC1 | |
| SCHEMBL378619 | 0.76 | CHEK1 (0.57) | TRPA1CTNNB1TCF7CDC7TRPM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912544-B | Preparation method of 5-bromo-1-methylindazole | 沧州普瑞东方科技有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-113912544-A | Preparation method of 5-bromo-1-methylindazole | 沧州普瑞东方科技有限公司 | 2022-01-11 | — | — | CN | claimed |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | BIOMEA FUSION, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12612379-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-16 | — | — | US | disclosed |
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-03-05 | — | — | US | disclosed |
| US-20260055105-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-02-26 | — | — | US | disclosed |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | KAINOS MEDICINE, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-20260015743-A1 | MEDIATED HYDROGEN ANODE FOR USE IN REDUCTIVE ELECTROSYNTHESIS | WISCONSIN ALUMNI RES FOUND (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004078116-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| CN-1492852-A | N-phenylpropylcyclopentyl substituted glutaramide derivatives as NEP inhibitors of FSAD | ������ҩ������˾ | 2004-04-28 | — | — | CN | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
| US-6660756-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617783-B2 | Heterocyclic GLP-1R agonists | GLP1R, GIPR, GPR119 | EGFR 1414/4885TRPA1 494/4885CTNNB1 631/4885 |
| US-20260015743-A1 | MEDIATED HYDROGEN ANODE FOR USE IN REDUCTIVE ELECTROSYNTHESIS | HAO2, HACL2, HVCN1 | EGFR 1616/4885TRPA1 1810/4885CTNNB1 1058/4885 |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | EGFR 2190/4885TRPA1 4709/4885CTNNB1 4752/4885 |
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | KRAS, NRAS, HRAS | EGFR 191/4885TRPA1 3703/4885CTNNB1 78/4885 |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GPR119 | EGFR 405/4885TRPA1 671/4885CTNNB1 2692/4885 |
| US-12612379-B2 | Inhibitors of APOL1 and methods of using same | APOL1, RNASE1, LOXL1 | EGFR 363/4885TRPA1 4530/4885CTNNB1 435/4885 |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | EGFR 2342/4885TRPA1 3588/4885CTNNB1 4621/4885 |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | EGFR 954/4885TRPA1 625/4885CTNNB1 1624/4885 |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | EGFR 3359/4885TRPA1 135/4885CTNNB1 3629/4885 |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | EGFR 2509/4885TRPA1 4721/4885CTNNB1 4751/4885 |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | EGFR 2342/4885TRPA1 3588/4885CTNNB1 4621/4885 |
| US-20260055105-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GIPR, GPR119 | EGFR 2103/4885TRPA1 332/4885CTNNB1 1863/4885 |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | IRAK4, IRAK1, IRAK2 | EGFR 703/4885TRPA1 1814/4885CTNNB1 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.